GranuFlo Lawsuit News: Bernstein Liebhard LLP Notes Filing of New GranuFlo Recall Claim in Illinois State Court

The Firm is evaluating GranuFlo lawsuits on behalf of individuals who allegedly suffered heart attacks, strokes, and other life-threatening heart events within 72 hours of a dialysis treatment with GranuFlo or NaturaLyte dialysis drugs.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Free Case Review
Since the GranuFlo recall, hundreds of dialysis patients and their families have filed lawsuits in courts around the country that echo the allegations put forth in this complaint.

New York, New York (PRWEB) February 12, 2014

Dialysis patients who allegedly suffered life-threatening heart events following administration of GranuFlo or NaturaLyte dialysis drugs continue to file GranuFlo lawsuits (http://www.thegranuflolawsuit.com/) in courts around the country, Bernstein Liebhard LLP reports. According to court documents, a New York woman filed suit against Fresenius Medical Care on January 31st for the alleged wrongful death of a relative from sudden cardiopulmonary arrest and a heart attack immediately following the administration of GranuFlo last February. The complaint, which was filed in Illinois’ St. Clair County Circuit Court, accuses Fresenius of failing to provide adequate warnings regarding GranuFlo’s association with an increased risk of heart attack and sudden cardiac death. (Case No. 14-L-134)

“Since the GranuFlo recall, hundreds of dialysis patients and their families have filed lawsuits in courts around the country that echo the allegations put forth in this complaint. Our Firm expects that the number of GranuFlo lawsuit filings will continue to grow in the coming months,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free legal reviews to dialysis patients who allegedly suffered cardiac arrest, heart attacks, stroke, sudden cardiac death or other serious heart events within 72 hours of the administration of GranuFlo or NaturaLyte.

GranuFlo Recall
The GranuFlo recall was announced in June 2012, following the release of an Urgent Product Notification by Fresenius Medical Care cautioning dialysis clinics about the potential association between inappropriate dosing of GranuFlo and NaturaLyte and the onset of serious cardiovascular events. The U.S. Food & Drug Administration (FDA) designated the notification a Class I recall, its most serious type of recall. A Class I recall indicates that use of a medical product could cause serious injury or death.

The New York Times also reported in June 2012 that the FDA had launched a probe of Fresenius Medical Care’s handling of the GranuFlo recall, after becoming aware of a memo the company issued in November 2011 to its own clinics regarding the risks associated with GranuFlo and NaturaLyte. However, nothing was done at that time to notify thousands of dialysis centers outside the Fresenius network about the potential dangers associated with the products.*

According to court documents, more than 460 GranuFlo lawsuits have been in courts around the country since the announcement of the GranuFlo and NaturaLyte recall. The majority of these claims have been filed in a multidistrict litigation now underway in U.S. District Court, District of Massachusetts. (In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428) Additional lawsuits have been consolidated at the state level in Massachusetts’ Middlesex County Superior Court. (In re Consolidated Fresenius Cases, No. MICV2013-03400-O)

Individuals who allegedly suffered serious heart events following the administration of GranuFlo or NaturaLyte may be entitled to compensation from Fresenius Medical Care. Find out more about filing a GranuFlo lawsuit at Bernstein Liebhard LLP’s website, or the Firm’s Facebook page: https://www.facebook.com/granuflolawsuit. For more information, and to arrange for a free case review, please call 800-511-5092.

*nytimes.com/2012/06/15/health/fda-investigates-fresenius-for-failure-to-warn-of-risk.html; New York Times, June 14, 2012

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this
advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.thegranuflolawsuit.com/
https://plus.google.com/115936073311125306742?rel=author